Anbio Biotechnology (NASDAQ:NNNN) Shares Gap Up - Here's Why

Key Points

• Shares gapped up pre-market from $26.60 to $31.00 but last traded around $26.46 on just 165 shares, suggesting a brief pre-open spike on very light volume.
• Weiss Ratings downgraded NNNN from "hold (c-)" to "sell (d+)," and MarketBeat shows a consensus Sell rating.
• The company reported quarterly earnings of $0.03 per share and its 50-day simple moving average is $25.19, near current trading levels.

Anbio Biotechnology (NASDAQ:NNNN - Get Free Report) shares gapped up before the market opened on Thursday . The stock had previously closed at $26.60, but opened at $31.00. Anbio Biotechnology shares last traded at $26.4570, with a volume of 165 shares traded.

Wall Street Analyst Weigh In

Separately, Weiss Ratings lowered shares of Anbio Biotechnology from a "hold (c-)" rating to a "sell (d+)" rating in a research note on Wednesday, April 1st. One research analyst has rated the stock with a Sell rating, According to MarketBeat.com, the stock has a consensus rating of "Sell".

Anbio Biotechnology Price Performance

The company's fifty day simple moving average is $25.19.

Anbio Biotechnology (NASDAQ:NNNN - Get Free Report) last issued its quarterly earnings data on Tuesday, April 7th. The company reported $0.03 earnings per share for the quarter.

Anbio Biotechnology Company Profile

Anbio Biotechnology is dedicated to the advancement of medical technology and the provision of in vitro diagnostics (IVD) products. Our unwavering commitment lies in transforming the diagnostics landscape on a global scale, fostering a paradigm shift towards personalized and decentralized diagnostic solutions. By doing so, we aim to significantly enhance patient prognosis and contribute to the betterment of healthcare worldwide. At Anbio Biotechnology, our extensive portfolio comprises an array of IVD products designed to cater to diverse diagnostic needs.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.